ACUT OTC
Accustem Sciences Inc.
1W: +12.5%
1M: -15.6%
3M: -52.7%
YTD: -83.4%
1Y: -91.0%
3Y: -86.5%
$0.14
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.2M
52W Range0.117-1.68
Volume1,100
Avg Volume3,914
Beta1.87
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOWendy E. Blosser
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2022-03-03
Websiteaccustem.com
5 Penn Plaza
New York City, NY 10001
US
New York City, NY 10001
US
+1 212 514 6245
About Accustem Sciences Inc.
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CERRONE GABRIELE M | P-Purchase | 5,000 | $1.40 | 2022-12-30 |
| CERRONE GABRIELE M | P-Purchase | 3,729 | $1.42 | 2022-12-02 |
| CERRONE GABRIELE M | P-Purchase | 24,500 | $1.05 | 2022-11-18 |
| CERRONE GABRIELE M | P-Purchase | 10,000 | $0.79 | 2022-08-01 |
| CERRONE GABRIELE M | P-Purchase | 20,000 | $0.50 | 2022-06-08 |